Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

785
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
785
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

827
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
827
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

1.0K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.0K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

718
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
718
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

771
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
771

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Artificial Intelligence for Evidence Synthesis of Emerging Biologics to Improve Skeletal Health in Osteogenesis Imperfecta: Systematic Review and Meta-Analysis.

Journal of medical Internet research·2026
Same author

Assessing microprocess clinical discrimination in psychodynamic psychotherapy: A vignette-based approach with expert consensus and sensitivity to structured exposure.

Psychotherapy research : journal of the Society for Psychotherapy Research·2026
Same author

Two years into an ongoing war: a six-wave prospective study of PTSD, depression, anxiety, and posttraumatic growth following the October 7, 2023, attack in Israel.

EClinicalMedicine·2026
Same author

Depression stigma, treatment-seeking intentions, and barriers to care among adolescents: demographic factors in a crowdsourced sample.

Psychiatry research·2026
Same author

Patient Experiences With GLP-1 Receptor Agonists.

JAMA network open·2026
Same author

Machine learning and deep learning-based drug-drug interactions prediction: a systematic review focused on anticancer drugs.

NPJ precision oncology·2026

Related Experiment Video

Updated: Mar 10, 2026

Automated Acoustic Dispensing for the Serial Dilution of Peptide Agonists in Potency Determination Assays
08:06

Automated Acoustic Dispensing for the Serial Dilution of Peptide Agonists in Potency Determination Assays

Published on: November 10, 2016

8.0K

Digital Microsteps as Scalable Adjuncts for Adults Using GLP-1 Receptor Agonists: A Randomized Clinical Trial.

Maya Adam1,2,3, Louis Fréget4,5, Till Bärnighausen3,6,7

  • 1Department of Pediatrics, Stanford University School of Medicine, Stanford, California.

JAMA Network Open
|March 9, 2026
PubMed
Summary
This summary is machine-generated.

Digitally delivered microsteps, with storytelling videos, increased behavioral expectations for lifestyle changes in adults using glucagon-like peptide-1 receptor agonists (GLP-1 RAs). These effects on health behaviors persisted for two weeks.

More Related Videos

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

665
Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
09:31

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

7.7K

Related Experiment Videos

Last Updated: Mar 10, 2026

Automated Acoustic Dispensing for the Serial Dilution of Peptide Agonists in Potency Determination Assays
08:06

Automated Acoustic Dispensing for the Serial Dilution of Peptide Agonists in Potency Determination Assays

Published on: November 10, 2016

8.0K
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

665
Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
09:31

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

7.7K

Area of Science:

  • Behavioral Science
  • Digital Health Interventions
  • Pharmacotherapy Adjuncts

Background:

  • The global uptake of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) necessitates scalable behavioral support for lifestyle changes.
  • Microsteps, or small behavior change prompts, offer a potential route to facilitate lifestyle adjustments alongside pharmacotherapy.

Purpose of the Study:

  • To evaluate if digitally delivered microsteps, enhanced with short video boosters, can increase behavioral expectations for adopting lifestyle behaviors in adults using GLP-1 RAs.
  • To compare the efficacy of a storytelling video versus a didactic video in augmenting microsteps.

Main Methods:

  • A 3-arm online randomized clinical trial involving 5054 adults using GLP-1 RAs.
  • Participants were randomized to receive written microsteps with a storytelling video, written microsteps with a didactic video, or a control condition.
  • Data were collected immediately post-exposure and at a 2-week follow-up.

Main Results:

  • Both microstep interventions significantly increased behavioral expectations compared to the control group, with effects diminishing by 2 weeks.
  • The storytelling video intervention showed greater effectiveness across most microsteps compared to the didactic video.
  • Immediate increases in hope and happiness were observed, and the storytelling group reported reduced sugar-sweetened beverage consumption at follow-up.

Conclusions:

  • A low-cost digital intervention using microsteps and video boosters can enhance behavioral expectations for health behaviors in GLP-1 RA users.
  • These findings suggest a potential role for such interventions as adjuncts to pharmacotherapy.
  • Further research is needed to determine if these stimulated expectations lead to sustained behavior change.